Kim H. T. Paraiso

发表

Expansion of Myeloid Suppressor Cells in SHIP-Deficient Mice Represses Allogeneic T Cell Responses1

C. Desponts, W. Kerr, J. Brayer, 2004, The Journal of Immunology.

GSK3β inhibition blocks melanoma cell/host interactions by downregulating N-cadherin expression and decreasing FAK phosphorylation

M. Herlyn, K. Smalley, E. Meggers, 2012, The Journal of investigative dermatology.

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression.

V. Sondak, K. Nathanson, A. Ribas, 2011, Cancer research.

Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis

L. Chin, M. Bosenberg, J. Dannenberg, 2010, Oncogene.

Melanoma and Other Skin Cancers

K. Smalley, K. Paraiso, Jobin K. John, 2012 .

Inappropriate Recruitment and Activity by the Src Homology Region 2 Domain-Containing Phosphatase 1 (SHP1) Is Responsible for Receptor Dominance in the SHIP-Deficient NK Cell1

R. Kendig, W. Kerr, H. Lawrence, 2007, The Journal of Immunology.

Dominance in the SHIP-Deficient NK Cell Phosphatase 1 (SHP1) Is Responsible for Receptor Src Homology Region 2 Domain-Containing Inappropriate Recruitment and Activity by the

R. Kendig, H. Lawrence, K. Paraiso, 2011 .

SHIP-Deficient NK Cell Responsible for Receptor Dominance in the Domain-Containing Phosphatase 1 (SHP1) Is the Src Homology Region 2 Inappropriate Recruitment and Activity by

R. Kendig, W. Kerr, H. Lawrence, 2007 .

Fibroblast-mediated drug resistance in cancer.

K. Smalley, K. Paraiso, Kim H. T. Paraiso, 2013, Biochemical pharmacology.

Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies.

K. Smalley, R. Kudchadkar, K. Paraiso, 2012, Cancer journal.

Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma.

K. Smalley, K. Paraiso, I. Fedorenko, 2011, Biochemical pharmacology.

Plasticity of extrachromosomal and intrachromosomal BRAF amplifications in mediating targeted therapy dosage challenges

T. Graeber, K. Paraiso, Kai Song, 2021, bioRxiv.

Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress.

T. Graeber, A. Ribas, L. Robert, 2018, Cancer cell.

Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS‐mutant melanoma

G. Gibney, K. Smalley, H. Lawrence, 2014, Pigment cell & melanoma research.

Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models

Kristina M. Ilieva, V. Petrenko, V. Sondak, 2014, Molecular Cancer Therapeutics.

Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma

V. Sondak, K. Smalley, J. Koomen, 2013, Molecular Cancer Therapeutics.

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy

V. Sondak, K. Flaherty, K. Smalley, 2010, British Journal of Cancer.

Chemical Therapeutics Inhibition of Wee 1 , AKT , and CDK 4 Underlies the Ef fi cacy of the HSP 90 Inhibitor XL 888 in an In Vivo Model of NRAS-Mutant Melanoma

V. Sondak, K. Smalley, J. Koomen, 2013 .

SHIP deficiency enhances HSC proliferation and survival but compromises homing and repopulation.

C. Desponts, W. Kerr, K. Paraiso, 2006, Blood.

Induced SHIP Deficiency Expands Myeloid Regulatory Cells and Abrogates Graft-versus-Host Disease1

R. Engelman, W. Kerr, K. Paraiso, 2007, The Journal of Immunology.

Evaluating Melanoma Drug Response and Therapeutic Escape with Quantitative Proteomics*

V. Sondak, G. Gibney, K. Smalley, 2014, Molecular & Cellular Proteomics.

The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms

V. Sondak, A. Ribas, K. Smalley, 2012, Clinical Cancer Research.

Vemurafenib Potently Induces Endoplasmic Reticulum Stress–Mediated Apoptosis in BRAFV600E Melanoma Cells

D. Schadendorf, K. Flaherty, C. Busch, 2013, Science Signaling.

Making sense of MEK1 mutations in intrinsic and acquired BRAF inhibitor resistance.

K. Smalley, K. Paraiso, Kim H. T. Paraiso, 2012, Cancer discovery.

SHIP1 Inhibition Increases Immunoregulatory Capacity and Triggers Apoptosis of Hematopoietic Cancer Cells

R. Engelman, Mi Young Park, W. Kerr, 2010, The Journal of Immunology.

Apoptosis of Hematopoietic Cancer Cells Immunoregulatory Capacity and Triggers SHIP1 Inhibition Increases

Engelman, W. Kerr, G. Fuhler, 2010 .

Measurement of constitutive MAPK and PI3K/AKT signaling activity in human cancer cell lines.

K. Smalley, J. Messina, K. Paraiso, 2010, Methods in enzymology.

Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype.

V. Sondak, K. Flaherty, J. Kirkwood, 2015, Cancer discovery.

Lineage extrinsic and intrinsic control of immunoregulatory cell numbers by SHIP

W. Kerr, K. Paraiso, Amy L. Hazen, 2012, European journal of immunology.

Cell Responses SHIP-Deficient Mice Represses Allogeneic T Expansion of Myeloid Suppressor Cells in

W. Kerr, J. Brayer, E. Sotomayor, 2013 .

Graft-versus-Host Disease Regulatory Cells and Abrogates Induced SHIP Deficiency Expands Myeloid

W. Kerr, K. Paraiso, T. Ghansah, 2007 .

SHIP limits immunoregulatory capacity in the T-cell compartment.

R. Engelman, W. Kerr, M. Collazo, 2009, Blood.

Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress.

T. Graeber, A. Ribas, L. Robert, 2018, Cancer cell.

Cutting Edge: Dominance by an MHC-Independent Inhibitory Receptor Compromises NK Killing of Complex Targets1

W. Kerr, K. Paraiso, C. Sentman, 2006, The Journal of Immunology.

SHIP Influences Signals from CD48 and MHC Class I Ligands That Regulate NK Cell Homeostasis, Effector Function, and Repertoire Formation

W. Kerr, M. Taniguchi, K. Paraiso, 2010, The Journal of Immunology.

Repertoire Formation Homeostasis , Effector Function , and CellMHC Class I Ligands That Regulate NK SHIP Influences Signals from CD 48 and

W. Kerr, M. Taniguchi, K. Paraiso, 2010 .

Plasticity of extrachromosomal and intrachromosomal BRAF amplifications in overcoming targeted therapy dosage challenges.

V. Bafna, T. Graeber, P. N. Rao, 2021, Cancer discovery.

Abstract 5370: PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

V. Sondak, K. Smalley, J. Messina, 2011 .

Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models

V. Sondak, K. Smalley, N. Wallis, 2014, Molecular Cancer Therapeutics.

Compromises NK Killing of Complex Targets MHC-Independent Inhibitory Receptor Cutting Edge : Dominance by an

W. Kerr, K. Paraiso, C. Sentman, 2006 .

Abstract 5111: Integrative phospho-proteomic and genomic analyses identify AXL as a potential biomarker and therapeutic target for NRAS-mutated melanoma

S. Eschrich, K. Nathanson, K. Smalley, 2011 .